GWM
REGN icon

Gibbs Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Gibbs Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.78M Buy
2,306
+1,765
+326% +$1.35M 0.23% 81
2025
Q4 		$431K Buy
541
+9
+2% +$6.11K 0.1% 221
2025
Q3 		$299K Sell
532
-72
-12% -$40.7K 0.07% 267
2025
Q2 		$317K Buy
604
+185
+44% +$103K 0.06% 277
2025
Q1 		$266K Buy
+419
New +$288K 0.06% 269

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Gibbs Wealth Management's REGN Position: Q1 2026 in Review

Gibbs Wealth Management increased its Regeneron Pharmaceuticals (REGN) stake by 326% in Q1 2026, buying an estimated $1.35M and bringing the position to 2,306 shares worth $1.78M. The position accounts for 0.23% of the portfolio, ranked #81.

Gibbs Wealth Management first reported a position in REGN in Q1 2025 and has held it in 5 quarters since. 1,400 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Gibbs Wealth Management held 2,306 shares of Regeneron Pharmaceuticals worth $1.78M as of Q1 2026.
  • Gibbs Wealth Management bought 1,765 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $1.35M.
  • Regeneron Pharmaceuticals made up 0.23% of Gibbs Wealth Management's portfolio in Q1 2026, its #81 holding.
  • Gibbs Wealth Management first reported a position in Regeneron Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • 1,400 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Gibbs Wealth Management's 13F filing for Q1 2026, filed 13 May 2026.